Results 81 to 90 of about 13,840,459 (217)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

Clinical Ophthalmology, 2023
Liesbeth Van Cleemput,1,2 Freya Peeters,1,2 Julie Jacob1,2 1Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium; 2Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, BelgiumCorrespondence: Liesbeth Van ...
Van Cleemput L, Peeters F, Jacob J
doaj  

Novel computer-based assessments of everyday visual function in people with age-related macular degeneration.

PLoS ONE, 2020
PurposeTo test the hypothesis that the performance in novel computer-based tasks of everyday visual function worsens with disease severity in people with non-neovascular age-related macular degeneration.MethodsParticipants with and without non ...
Bethany E Higgins, Deanna J Taylor, Wei Bi, Alison M Binns, David P Crabb   +4 more
doaj   +1 more source

Intravitreal bevacizumab for neovascular age-related macular degeneration

Philippine Journal of Ophthalmology, 2009
Objectives: Anti-vascular endothelial growth factor (anti-VEGF) drugs delivered intravitreally have been proven effective and safe for the treatment of patients diagnosed with neovascular age-related macular degeneration (ARMD).
Junn R. Pajarillo, MD, Harvey S. Uy,MD, Milagros H. Arroyo MD, MPH   +2 more
doaj  

DIFFERENTIAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-A ISOFORMS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

, 2015
Purpose: To investigate the role of vascular endothelial growth factor-A ( VEGF-A) isoforms in neovascular age-related macular ...
Grisanti, Salvatore, Tura, Aysegul, Grisanti, Swaantje, Lueke, Matthias, TATAR KARTALOĞLU, OLCAY, Lueke, Julia, Zhu, Qi   +6 more
core   +1 more source

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh A. Patel   +5 more
doaj   +1 more source

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

Journal of Current Ophthalmology, 2019
Purpose: To report the results of aflibercept treatment in treatment-naive neovascular age-related macular degeneration (AMD) patients and suggest a suitable treatment algorithm for routine clinical practice.
Erkan Unsal, Mehmet Ozgur Cubuk
doaj   +1 more source

OCT Angiography Helps Distinguish Between Proliferative Macular Telangiectasia Type 2 and Neovascular Age-Related Macular Degeneration

, 2018
To demonstrate the advantage of optical coherence tomography angiography (OCTA) for the diagnosis and management of proliferative macular telangiectasia type 2 (MacTel2) masquerading as neovascular age-related macular degeneration (AMD).info:eu-repo ...
Elie H. Motulsky, Motulsky, Elie H, Zheng, Fang, Fang Zheng, Gregori, Giovanni, Motulsky, Elie, Rosenfeld, Philip J, Philip J. Rosenfeld, João Rafael de Oliveira Dias, Edith Pérez de López, Giovanni Gregori, de López, Edith Pérez, de Oliveira Dias, João Rafael   +12 more
core   +1 more source

Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration

Journal of Ophthalmology, 2015
Herein, we review the association between vitreomacular adhesion (VMA) and neovascular age-related macular degeneration (AMD). Meta-analyses have shown that eyes with neovascular AMD are twice as likely to have VMA as normal eyes.
Eui Chun Kang, Hyoung Jun Koh
doaj   +1 more source

Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch   +8 more
wiley   +1 more source

Current perspectives on ranibizumab

Clinical Ophthalmology, 2015
Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing
Dedania VS, Bakri SJ
doaj